Citizens increased argenx's price target to $944 from $925
The rating remains Market Outperform
The adjustment follows positive ocular MG treatment results
Analyst consensus suggests 32% upside potential for argenx
📖 Full Retelling
Investment firm Citizens raised its price target on biotechnology company argenx SE (NASDAQ:ARGX) to $944 from $925, citing positive results from the company's ocular myasthenia gravis (MG) treatment program, while maintaining its Market Outperform rating on the stock. The new price target aligns with the broader analyst consensus, with the average target suggesting 32% upside potential for argenx shares. This adjustment comes as argenx continues to demonstrate promising clinical data for its treatments targeting rare autoimmune diseases, particularly in the area of ocular myasthenia gravis, a rare neuromuscular disorder affecting the eye muscles. The increased valuation reflects growing confidence in argenx's pipeline and its potential to capture significant market share in the specialized biotechnology sector.
Nasdaq Stock Market (National Association of Securities Dealers Automated Quotations) is an American stock exchange, the second-largest by market cap on the list of stock exchanges, and the first fully electronic stock market. The exchange is based in Manhattan, New York City, and is among the most ...
Citizenship is a membership and allegiance to a sovereign state. Though citizenship is often conflated with nationality in today's English-speaking world, international law does not usually use the term citizenship to refer to nationality; these two notions are conceptually different dimensions of c...
Investing.com - Citizens raised its price target on argenx SE (NASDAQ:ARGX) to $944 from $925 while maintaining a Market Outperform rating. The new target aligns with the broader analyst consensus, with the average target suggesting 32% upside potential. According to InvestingPro
